Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study.
Xu D, Yang Y, Yin Z, Tu S, Nie D, Li Y, Huang Z, Sun Q, Huang C, Nie X, Yao Z, Shi P, Zhang Y, Jiang X, Liu Q, Yu G.
Xu D, et al. Among authors: huang c, huang z.
Blood Cancer J. 2023 Nov 13;13(1):168. doi: 10.1038/s41408-023-00941-4.
Blood Cancer J. 2023.
PMID: 37957175
Free PMC article.
No abstract available.